Keytruda

Active substance

Pembrolizumab

Holder

MSD Belgium BV/SRL

Statut

Running

Indication

for the adjuvant treatment of renal cell carcinoma patients with intermediate-high risk and high risk of recurrence after nephrectomy.

Public documents

Approbation

Information for the patient

Informed consent

Last update

02/10/2024
Last updated on 07/11/2024